JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4976
Silvercrest Asset Management
SAMG
$81.5M
| $155K | ﹤0.01% |
8,513
-1,241
| -13% | -$22.4K |
2017 Q4
21 quarters
|
|
|
XXII
4977
22nd Century Group
XXII
$623K
| – | – |
0
| – | – |
2018 Q2
19 quarters
|
|
|
PPT
4978
Franklin Premier Income Trust
PPT
$313M
| $154K | ﹤0.01% |
+43,281
| New | +$160K |
2023 Q1
0 quarters
|
|
4979
CALL
Hershey
HSY
$32.5B
| $153K | ﹤0.01% |
+600
| New | +$141K |
2023 Q1
0 quarters
|
|
4980
Legacy Housing
LEGH
$698M
| $153K | ﹤0.01% |
6,702
+1,750
| +35% | +$35.4K |
2019 Q1
16 quarters
|
|
4981
Parke Bancorp
PKBK
$386M
| $153K | ﹤0.01% |
8,585
-2,251
| -21% | -$44.8K |
2021 Q4
5 quarters
|
|
4982
AllianzIM U.S. Equity Buffer20 Jan ETF
JANW
$358M
| $152K | ﹤0.01% |
+5,513
| New | +$149K |
2023 Q1
0 quarters
|
|
|
AFCG
4983
AFC Gamma
AFCG
$74.4M
| $152K | ﹤0.01% |
18,290
+4,335
| +31% | +$44.1K |
2021 Q2
7 quarters
|
|
4984
Global Water Resources
GWRS
$235M
| $152K | ﹤0.01% |
12,238
+2,880
| +31% | +$38.9K |
2017 Q4
21 quarters
|
|
|
LUXE
4985
LuxExperience B.V.
LUXE
$1.4B
| $152K | ﹤0.01% |
21,620
-41,633
| -66% | -$378K |
2022 Q3
2 quarters
|
|
4986
PUT
SolarEdge
SEDG
$2.1B
| $152K | ﹤0.01% |
500
-300
| -38% | -$91.5K |
2022 Q2
3 quarters
|
|
4987
Afya
AFYA
$1.21B
| $151K | ﹤0.01% |
13,574
-307,507
| -96% | -$4.04M |
2022 Q1
4 quarters
|
|
4988
Gossamer Bio
GOSS
$66.7M
| $151K | ﹤0.01% |
1,495
-9,975
| -87% | -$1.53M |
2019 Q1
16 quarters
|
|
|
ITIC
4989
Investors Title Co
ITIC
$560M
| $151K | ﹤0.01% |
1,001
-341
| -25% | -$52.4K |
2017 Q3
22 quarters
|
|
4990
LifeMD
LFMD
$136M
| $151K | ﹤0.01% |
+88,792
| New | +$157K |
2023 Q1
0 quarters
|
|
|
NHS
4991
Neuberger High Yield Strategies Fund Inc
NHS
$227M
| $151K | ﹤0.01% |
+17,705
| New | +$151K |
2023 Q1
0 quarters
|
|
4992
TRI-Continental Corp
TY
$1.85B
| $151K | ﹤0.01% |
5,694
+717
| +14% | +$19.2K |
2022 Q4
1 quarter
|
|
4993
Design Therapeutics
DSGN
$774M
| $150K | ﹤0.01% |
25,956
+6,156
| +31% | +$46K |
2021 Q2
7 quarters
|
|
|
ESSA
4994
DELISTED
ESSA Bancorp
ESSA
| $150K | ﹤0.01% |
9,581
+9,353
| +4,102% | +$180K |
2017 Q4
21 quarters
|
|
4995
PepGen
PEPG
$163M
| $150K | ﹤0.01% |
12,247
+3,771
| +44% | +$59K |
2022 Q2
3 quarters
|
|
4996
Red Violet
RDVT
$1.27B
| $150K | ﹤0.01% |
8,486
+1,771
| +26% | +$38K |
2021 Q4
5 quarters
|
|
|
SLNO
4997
DELISTED
Soleno Therapeutics
SLNO
| $150K | ﹤0.01% |
69,875
+69,869
| +1,164,483% | +$157K |
2020 Q2
11 quarters
|
|
|
ICPT
4998
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $150K | ﹤0.01% |
+11,200
| New | +$194K |
2023 Q1
0 quarters
|
|
|
CGC
4999
Canopy Growth
CGC
$375M
| $150K | ﹤0.01% |
8,489
+7,910
| +1,366% | +$188K |
2018 Q2
19 quarters
|
|
|
VOXX
5000
DELISTED
VOXX International Corporation Class A
VOXX
| $149K | ﹤0.01% |
12,075
+12,056
| +63,453% | +$131K |
2022 Q4
1 quarter
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.